Lumida
/DGX
⌘K
Quest Diagnostics Inc

Quest Diagnostics Inc

DGX
$210.68USD↑+0.61%+1.27 today

MARKET CAP

23.3B

P/E (TTM)

20.8x

FWD P/E

18.6x

DAY RANGE

$209 – $214

52W RANGE

$165
$219

AI Summary

Stalk
StalkMedium

DGX remains in a Stage 2 advancing regime with bullish medium- and long-term biases, but price is currently extended above rising EMAs in an overbought condition. Under the Stable strategy’s preference for controlled engagement, patience is warranted for a pullback into the 9/21 EMA zone or near the 50 DMA to provide a more favorable entry.

  • ↑Q1 revenue rose 9.2% to $2.9B; adjusted EPS grew 13% to $2.50.
  • ↑Consumer health segment (questhealth.com) up ~30–40% YoY, enhancing revenue mix.
  • ↓Elevated leverage risk may pressure cash flows under stress.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Quest Diagnostics Incorporated (NASDAQ: DGX) is a leading provider in the healthcare sector, specializing in diagnostic information services and laboratory testing. The company is strategically expanding its market presence through advanced diagnostics, consumer health initiatives, and innovative solutions. Positioned favorably within the healthcare value chain, Quest is an essential partner for clinical customers, responding adeptly to evolving patient needs and trends towards preventative health care.

Bull says

  • ↑Q1 revenue rose 9.2% to $2.9B; adjusted EPS grew 13% to $2.50.
  • ↑Consumer health segment (questhealth.com) up ~30–40% YoY, enhancing revenue mix.
  • ↑AD DETECT Alzheimer’s tests demand more than doubled in Q3.
  • ↑Automation and AI boosted customer service productivity by 40%.
  • ↑Preventive health demand rising; new Haystack MRD test scales cancer diagnostics.
  • ↑Attractive dividend yield (~0.66%) and strong momentum factors support valuation.

Bear says

  • ↓Elevated leverage risk may pressure cash flows under stress.
  • ↓Weak organic growth outlook amid tough comps may limit revenue gains.
  • ↓Weather volatility hit $9M revenue in Q1, creating volume swings.
  • ↓Integration and startup costs from partnerships may compress near-term margins.
  • ↓PAMA Medicare reimbursement cuts could shave ~$100M revenue if unaddressed.
  • ↓Weak profitability metrics and high volatility factors signal downside risk.

Investment themes with DGX

High Dividend Yield↑ +0.32%

Companies paying above-average dividends

AVGO · JPM · XOM
Health Care Providers↓ -0.61%

UNH · CVS · HCA

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 04-23-2026neutral

Transcript signals

Bull points

  • We are listing the tests on our test menu so that Quest physicians can order that test. And patients, regardless if it came from a Quest physician or another physician, patients can bring that requisition to a Quest PSC, and we'll draw the blood and send the specimen on to Garden's lab.
  • During the first quarter, we grew revenues over 9% almost entirely from organic revenue growth on broad-based demand for our clinical innovations, expansion into new clinical areas, and collaborations with elite healthcare and consumer health organizations.
  • In addition, we grew adjusted diluted earnings per share by approximately 13%, supported by productivity gains from our deployment of automation and AI across our operations, both in and outside our labs.

Bear points

  • It's early days to talk about EPS ramp in terms of the dilution or the improvement over the course of the year.
  • some higher fuel costs that are going to be impacting the second half of the year.
  • some of the fuel costs that I mentioned, I mean, they basically start now, right? So it's not like just the second half that you have to phase those across.
Read full transcript analysis ›